Despite strong third-quarter revenues, BioNTech has softened its 2024 sales guidance in light of changes to Covid-19 vaccine ...

BioNTech said that its VEGF bispecific sets it apart from competitors because of its mechanism and how it plans to ...

Gene therapy has emerged as a transformative technology, offering life-changing treatments for conditions with few options.

Viking Therapeutics' highly anticipated readout of its oral anti-obesity pill showed a placebo-adjusted weight loss of 6.8% ...

Plus, news about Disc Medicine, OSE Immunotherapeutics, CrossBridge Bio, Lomond Therapeutics, Relief Therapeutics and Renexxion: Novo Nordisk, Ascendis Pharma ink deal: The Danish drugmaker will pay ...

Well behind Novo Nordisk and Eli Lilly in the obesity race, AstraZeneca came to this year's ObesityWeek with three assets in hand as it hopes to ...

For years, drug developers working to treat an advanced form of fatty liver disease known as MASH were chasing wide-open terrain. There were no products on the market, millions of ...

The European Commission has set Dec. 6 as its deadline to decide if Novo Holdings’ billion-dollar acquisition of Catalent passes its antitrust review, according to a ...

The biopharma industry has been a bipartisan political target in recent years. But in the 2024 presidential election, details are scarce around key issues that could impact drugmakers. Drug pricing ...

Novo Nordisk’s wildly popular anti-obesity drug Wegovy helped heart disease patients end up in the hospital less often and ...

CinFina Pharma, a subsidiary of the hub-and-spoke biotech CinRx, shared early-stage data for two of its Janssen-licensed ...

Another inflammation and immunology startup has attracted big bucks. On Thursday, Evommune announced a $115 million raise to ...